Calliditas Therapeutics AB (publ) CALT
At closeSep 20, 2024, 4:00 PM EDT
52-week range unavailable
- Market cap
- 1.10B
- Revenue (ttm)
- 1.60B
- Profit margin
- -30.00%
- Shares out
- 27.02M
- Forward P/E
- 6.33
- Volume
- 9.79K
- Open
- 40.00
- Previous close
- 40.00
- Day's range
- 40.00 – 43.00
- Beta
- 1.46
- Analysts
- Hold
- Price target
- 39.25 (-1.9%)
- Earnings date
- Nov 11, 2024
Key statistics
- Enterprise value
- 2.37B
- PEG ratio
- 0.00
- Price / sales
- 0.68
- Price / book
- 20.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 107.80%
- Free cash flow
- -210.84M
- Total cash
- 797.28M
- Total debt
- 1.01B
- Return on equity
- -157.20%
- Short % of float
- 0.02%
- 50-day average
- 39.65
- 200-day average
- 29.60
Analyst view
Consensus: hold
- Target (low)
- 39.00
- Target (mean)
- 39.25
- Target (high)
- 40.00
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell0
Next earnings
Nov 11, 2024
Expected Nov 11, 2024. Consensus EPS estimate -0.22.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -0.05 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.13 | — | — | — |
| May 23, 2024 | Mar 1, 2024 | -0.14 | — | — | — |
| Feb 21, 2024 | Dec 1, 2023 | -0.10 | — | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -0.22 | — | — | — |
| Aug 17, 2023 | Jun 1, 2023 | -0.25 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 20, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 17, 2023 | Guggenheim | main | Neutral | Neutral |
| Jun 19, 2023 | HC Wainwright & Co. | init | — | Buy |
| Feb 28, 2023 | Guggenheim | init | — | Neutral |
| Feb 23, 2023 | Citigroup | main | — | Buy |
About Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Sweden
- Website
- calliditas.se
News
Financial Survey: MindWalk (NASDAQ:HYFT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) 
Analyzing Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) 
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & Palatin Technologies (PINK:PTNT) Critical Analysis 
Head-To-Head Review: AngioSoma (OTCMKTS:SOAN) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT) 
Evofem Biosciences (NASDAQ:EVFM) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Head-To-Head Survey 
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm 
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) 
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei 
Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript 
Calliditas Interim Report January to June 2024
Your note
Sign in to keep a note on CALT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 2.52% | 750,000 | 11.88M | Jun 29, 2023 |
| Deutsche Bank Aktiengesellschaft | 0.30% | 90,550 | 1.43M | Jun 29, 2023 |
| Ironwood Investment Management, LLC | 0.09% | 27,214 | 431.05K | Jun 29, 2023 |
| Optiver Holding B.v. | 0.02% | 5,030 | 79.67K | Jun 29, 2023 |
| Morgan Stanley | 0.01% | 2,656 | 42.07K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.02% | 5,831 | 98.83K | May 30, 2023 |